Table 1

Baseline and procedural characteristics for patients in the main development cohort

Variable*Summary (n=6339)Missing (% of 6339)
Age, mean (range)81.25 (29–101)0 (0)
Female, n (%)2927 (46.17)22 (0.35)
Non-Caucasian, n (%)249 (3.93)65 (1.03)
Diabetic, n (%)1463 (23.08)35 (0.55)
Current or ex-smoker, n (%)3240 (51.11)245 (3.86)
Height (m), mean (range)1.65 (1.10–2.36)156 (2.46)
Weight (kg), mean (range)74.23 (32–190)129 (2.04)
Creatinine, µmol/L, mean (range)114.2 (29–1044)71 (1.12)
Dialysis, n (%)122 (1.92)66 (1.04)
MI within 30 days of TAVI, n (%)60 (0.95)33 (0.52)
Pulmonary disease, n (%)1777 (28.03)87 (1.37)
Cerebrovascular disease, n (%)913 (14.40)34 (0.54)
Extracardiac arteriopathy, n (%)1462 (23.06)84 (1.33)
Calcified aorta, n (%)1076 (16.97)73 (1.15)
Sinus rhythm, n (%)4054 (63.95)106 (1.67)
Previous cardiac surgery, n (%)1990 (31.39)35 (0.55)
Prior BAV, n (%)694 (10.95)32 (0.50)
Previous PCI, n (%)1272 (20.07)34 (0.54)
Critical preoperative state, n (%)98 (1.55)81 (1.28)
NYHA class IV, n (%)1089 (17.18)42 (0.66)
Poor mobility, n (%)662 (10.44)3423 (54.00)
CSHA frail, n (%)1165 (18.38)3419 (53.94)
KATZ<6, n (%)851 (13.42)3696 (58.31)
PA systolic >60 mm Hg, n (%)740 (11.67)1816 (28.65)
Aortic peak gradient, mean (range)74.56 (3.35–200)259 (4.09)
Aortic valve area, mean (range)0.68 (0.2–2)388 (6.12)
LVEF<50%, n (%)2421 (38.19)55 (0.87)
LMS>50%, n (%)275 (4.34)138 (2.18)
Non-elective procedure, n (%)790 (12.46)7 (0.11)
Non-transfemoral access, n (%)1607 (25.35)13 (0.21)
Valve type29 (0.46)
 Edwards SAPIEN valve, n (%)3553 (56.05)
 Medtronic CoreValve, n (%)2531 (39.93)
 Other, n (%)226 (3.57)
  • *Variable definitions are given in online supplementary table 1.

  • BAV, balloon aortic valvuloplasty; CSHA, Canadian Study of Health and Aging; LMS, left main stem disease; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association Functional Classification; PA, pulmonary artery; PCI, percutaneous coronary intervention; TAVI, transcatheter aortic valve implantation.